Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026377 · ClinicalTrials.gov registry record · Phase 1
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00026377: Completed Phase 1 study, sponsored by University of Chicago.
NCT00026377 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026377, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining SU5416, hormone therapy, and radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus hormone therapy and radiation therapy in treating patients who have prostate cancer.
Interventions
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG bicalutamide
- DRUG flutamide
- DRUG SU5416
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2001-11 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
What the finished NCT00026377 record still lists
NCT00026377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00026377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026377 about?
NCT00026377 is a clinical study titled "SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation thera...
What is the current status of trial NCT00026377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2001-11. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00026377?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin acetate (DRUG), bicalutamide (DRUG), flutamide (DRUG), SU5416 (DRUG).
Who is sponsoring clinical trial NCT00026377?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00026377's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia